ホルモン抵抗性前立腺癌転移巣に対する治療法について

Abstract

ホルモン抵抗性前立腺癌転移巣に対する治療法について報告した.著者等の企図する遺伝子治療は, 1)HSV-TKタンパク質の全ての翻訳領域を含む遺伝子を用いた「自殺遺伝子治療」であり, TSV-TK遺伝子により最終的に三リン酸化された代謝産物は癌細胞のDNA合成を阻害し, DNA鎖の分裂およびアポトーシスを引き起こした.2)HSV-TK遺伝子の上流に臓器特異性のマウスOCプロモーターを組み込んだアデノウイルスベクター(ad-OC-TKベクター)を前立腺癌の局所再発巣へ直接, CT・超音波ガイド下に局所注入した.OCプロモーターを活性できない正常細胞ではHSV-TKタンパクは発現せず, ad-OC-TKベクターには感染しなかった.3)我が国において, 2名の患者にad-OC-TKベクター投与を実施し, 投与後1日目の血中と1週間後の組織中にウイルスDNAを検出し, 組織中にのみHSV-TKmRNAが検出された.2例とも重篤な副作用は認めなかった

We selected bone-metastatic prostate cancer as the target form of recurrent prostate cancer and developed a suicide-gene therapy based on an adenovirus vector with an organ-specific osteocalcin promoter. Related clinical studies have already been conducted in the United States at the University of Virginia, where results so far have established the safety of this therapy. In the present paper, in addition to presenting the results of these gene-therapy studies from the basic research to the clinical stage, we discuss the clinical studies begun by our group in August 2003. In the 21st century, therapeutic systems in use are undergoing major changes. Gene therapy is likely to become an important therapeutic option in recurrent prostate cancer. In terms of theory and technology however, this form of treatment is still at a very immature stage of development. We look forward to evolution in this field to provide an established treatment for recurrent prostate cancer and are committed to actively continuing with the development of gene therapy through translational research.